| 标题 |
专利、报告等 Phase 2 Study of High-Dose Furmonertinib (160 mg Daily) as First-Line Treatment for EGFR-Mutated Advanced NSCLC With Brain Metastases
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | [16]Gong Y, Li M, Zhang H, et al. Phase 2 Study of High-Dose Furmonertinib (160 mg Daily) as First-Line Treatment for EGFR-Mutated Advanced NSCLC With Brain Metastases[C]. Singapore: 2025 ESMO Asia, 2025. Abstract LBA5. |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)
张欢馨
Kao
cdercder
22336
v0id
美满又蓝
ddd
学术文献互助
ricardo
yzy
sagitar
OK
科研狗
aubusson
Enigma_GEB
Nole
四喜丸子
lixinglei
MozzieMiao
凌时爱吃零食
皖公网安备34019202002308
